Industry coverage tracks the money around peptides: Eli Lilly and Novo Nordisk earnings, pipeline shifts, M&A, IPOs, peptide CDMO capacity, and the telehealth and pharmacy economy that GLP-1s built.
The two stories that keep moving the most market cap: how fast oral GLP-1s reach approval (orforglipron, oral semaglutide, oral wegovy, danuglipron's exit), and what happens to the compounded-peptide channel as the FDA tightens. Hims, Ro, LifeMD, GoodRx, and Amazon Pharmacy have all rerouted distribution in the past year. Behind them, contract manufacturers like Bachem, PolyPeptide, and BASF have been the bottleneck no one talked about until they were.
Stories here name the company, the deal, and the dollars. Earnings, partnership, regulatory hit — whatever moved the share price gets covered.
A DelveInsight market analysis published April 20 projects 7.3% CAGR growth in the pheochromocytoma and paraganglioma treatment market through 2036, driven by SSTR2 analogs and peptide receptor radionuclide therapies including Novartis's Lutathera (lutetium-177 dotatate). PRRT remains one of the few FDA-approved peptide therapeutics for rare neuroendocrine tumors, binding SSTR2 to deliver targeted radiation.
The AACR 2026 Opening Plenary Session — 'Precision, Partnership, Purpose: Advancing Cancer Science to Save Lives Globally' — runs Sunday April 19, 9:30-11:30 a.m. PT. Cochaired by Paul Mischel (Stanford) and Alice Shaw (Dana-Farber), speakers include Carl June (Penn, armored CAR-T for solid tumors, glioblastoma), Georg Winter (AITHYRA), Regina Barzilay (MIT), and Charles Sawyers (MSK). The program sets the tone for a meeting in which peptide-based modalities, ADCs, and PDCs are taking center stage.
Verismo Therapeutics announced a $28 million investment from HLB Innovation to accelerate clinical development of its KIR-CAR platform, timed to the company's first-ever presentation of SynKIR-110 Phase 1 (STAR-101) multi-chain KIR-CAR clinical data in the AACR 2026 Late-Breaking Clinical Trials plenary (April 20). Verismo is a Penn/Carl June spinout using a modified NK-cell-derived receptor and DAP12 pairing to improve T-cell persistence.
PharmaTher Holdings filed a U.S. provisional patent on April 13 for stabilized peptide compositions delivered via its PharmaPatch microneedle platform, covering formulations for BPC-157, GHK-Cu, TB-500, KPV, and multi-peptide combinations. The April 16 announcement positions PharmaTher to capture needle-free delivery share if the FDA's July PCAC meeting moves peptides back to Category 1. Three of the four compounds are on the July agenda.
The European Society of Clinical Microbiology & Infectious Diseases (ESCMID) Global 2026 opened today at Messe München, running April 17-21 with ~18,000 international participants. Antimicrobial resistance dominates the agenda, with presentations featuring novel antimicrobial peptides, peptide-antibody hybrids, and AI-driven AMP discovery platforms. ESCMID is the largest international clinical microbiology and infectious diseases conference worldwide.
ApexOnco analysis frames AACR 2026 as a breakout moment for private peptide-based biotechs. Circle Pharma (macrocyclic peptides), Bicycle Therapeutics (bicyclic peptide drug conjugates), and SignaBlok (TREM-1 peptide) all landed prominent slots. Antibody-drug and peptide-drug conjugates remain the dominant theme, with conjugate-related abstracts outpacing any other modality in the clinical late-breaker sessions.
CNBC analysis frames Hims & Hers Health as the biggest direct-to-consumer beneficiary of the FDA's July PCAC meeting. Hims acquired a California peptide manufacturing facility in 2025 and can convert its GLP-1 compounding infrastructure to peptide production. The stock closed up 11.07% on April 16 after the FDA announcement; Bank of America raised its price target from $21 to $25, citing the platform's conversion potential.
The American Association for Cancer Research (AACR) Annual Meeting 2026 opens April 17 at the San Diego Convention Center, running through April 22 with 9,500+ sessions, 575 clinical abstracts, 56 clinical trial plenary talks, and 393 late-breaking posters. Multiple peptide biotechs — including Bicycle Therapeutics, Circle Pharma, SignaBlok, and Oncolytics Biotech — are presenting new clinical and preclinical data on macrocyclic peptides, bicyclic peptide drug conjugates, and peptide-based immunotherapies.
Novo Nordisk and OpenAI announced a partnership to deploy AI across R&D, manufacturing, and corporate functions, with pilot programs launching immediately and full integration targeted by end of 2026. The deal positions Novo to analyze complex datasets, identify new drug candidates, and compress R&D timelines as it fights to claw back market share from Eli Lilly. OpenAI will also provide AI literacy training to Novo's global workforce.
Motley Fool analysis argues that retatrutide — Lilly's triple GLP-1/GIP/glucagon agonist showing up to 28.7% weight loss in Phase 3 TRIUMPH-4 — is the one thing that could firmly cement Lilly's dominance in the obesity drug market. With seven additional Phase 3 readouts expected in 2026 and a projected 2028 launch, retatrutide positions Lilly to extend its lead over Novo Nordisk.
Fifty 1 Labs (OTC:FITY) announced the expansion of its peptide discovery and clinical research strategy targeting musculoskeletal health, recovery, and performance. The company is building a proprietary peptide discovery engine focused on MSK biology, combining AI-enabled design with staged clinical development for muscle, tendon, ligament, and bone conditions — an area largely overlooked by the GLP-1 dominated peptide pipeline.
Enhanced, an elite sports performance and direct-to-consumer peptide company, formally welcomed the FDA's Pharmacy Compounding Advisory Committee meeting schedule. CEO Maximilian Martin stated the reclassification will move peptides 'out of the grey market' and enable licensed compounding access. Enhanced plans to expand its Live Enhanced platform to offer additional peptides once they are formally moved to Category 1.
The three-day In-Cosmetics Global 2026 event opened at Paris Expo Porte de Versailles on April 15, with peptide actives a defining theme. BASF launched NeoHelix Regenerate (41% reduction in damaged collagen at 56 days) and SkinNexus Collag3n (recombinant Collagen III fragment). Gelita showcased its bioactive collagen peptide Verisol for skin elasticity, hydration, and wrinkle reduction.
Hims & Hers Health Inc. jumped as much as 12% after the FDA's advisory panel announcement, with investors betting the telehealth company will benefit from expanded legal access to compounded peptide therapies. RFK Jr. stated on X that this action would 'immediately begin shifting demand away from the black market.'
Novo Nordisk's oral Wegovy 4mg dose increased from the introductory $149/month to $199/month effective April 15, as previously announced. The 1.5mg starter dose remains at $149/month, while maintenance doses (9mg, 25mg) stay at $299/month. The price increase applies to the NovoCare self-pay channel.
The Drug Discovery Chemistry Oral & Macrocyclic Peptides Summit (April 14-15, San Diego) convenes as 66 cyclic peptide drugs have gained global approval and the field races to solve oral bioavailability. Key advances include Chugai's Luna18 achieving 21-47% oral bioavailability and Merck's macrocyclic PCSK9 inhibitor enlicitide delivering injectable-level results in pill form.
CNN published a comprehensive consumer guide distinguishing FDA-approved peptide therapeutics from unregulated wellness peptides. Experts warn that rising demand is fueling an online black market with unknown safety risks, while HHS Secretary RFK Jr. pushes to relax restrictions.
Peter Attia devoted a full AMA episode to peptides, building a framework for evaluating any compound based on mechanism, evidence quality, and safety. The episode examines BPC-157, SS-31, melanotan-II, and CJC-1295, addresses grey-market risks, and maps which areas of medicine stand to benefit most.